Determining the right care plan and treatment for your AAV may require numerous doctors. Learn their roles and when to ...
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, ...
Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...
CHARLESTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...
Nearly all (96%) patients with active AAV enrolled in the study achieved remission, with a median time to remission of 77 days. Early glucocorticoid withdrawal is feasible and was well tolerated in ...